Evidence map›Paper›PMID 33681294›Full record

ReviewFrontiers in molecular biosciences2021

Metabolic Modeling to Interrogate Microbial Disease: A Tale for Experimentalists.

Fabrice Jean-Pierre, Michael A Henson, George A O'Toole

Abstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. How is the human microbiome linked to kidney stones?Frontiers in cellular and infection microbiology · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fabrice Jean-PierreDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
Michael A HensonDepartment of Chemical Engineering and Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA, United States.
George A O'TooleDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.

Funding

cdiGMP regulation of Biofilm FormationR37AI083256 · NIAID · DARTMOUTH COLLEGE · PI O'TOOLE, GEORGE A. · 2014 to 2023
$4.7M
Metabolic Basis of Bacterial Community Function in the Cystic Fibrosis AirwayR01AI155424 · NIAID · DARTMOUTH COLLEGE · PI O'TOOLE, GEORGE A. · 2021 to 2025
$2.3M
NIAID NIH HHS R01 AI155424NIAID NIH HHS R37 AI083256
6 · The paper itself

Abstract

The explosion of microbiome analyses has helped identify individual microorganisms and microbial communities driving human health and disease, but how these communities function is still an open question. For example, the role for the incredibly complex metabolic interactions among microbial species cannot easily be resolved by current experimental approaches such as 16S rRNA gene sequencing, metagenomics and/or metabolomics. Resolving such metabolic interactions is particularly challenging in the context of polymicrobial communities where metabolite exchange has been reported to impact key bacterial traits such as virulence and antibiotic treatment efficacy. As novel approaches are needed to pinpoint microbial determinants responsible for impacting community function in the context of human health and to facilitate the development of novel anti-infective and antimicrobial drugs, here we review, from the viewpoint of experimentalists, the latest advances in metabolic modeling, a computational method capable of predicting metabolic capabilities and interactions from individual microorganisms to complex ecological systems. We use selected examples from the literature to illustrate how metabolic modeling has been utilized, in combination with experiments, to better understand microbial community function. Finally, we propose how such combined, cross-disciplinary efforts can be utilized to drive laboratory work and drug discovery moving forward.

Indexed as

cystic fibrosisdrug discoverygut microbiomemetabolic modelingmetabolite cross-feeding

Identifiers

PMID33681294
PMCPMC7930556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.